STOCK TITAN
  1. Home
  2. News
  3. PDSB

PDS Biotechnology Corporation - $PDSB STOCK NEWS

Welcome to our dedicated page for PDS Biotechnology Corporation news (Ticker: $PDSB), a resource for investors and traders seeking the latest updates and insights on PDS Biotechnology Corporation stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect PDS Biotechnology Corporation's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of PDS Biotechnology Corporation's position in the market.

News
PDS Biotech Announces PDS0101 Combined with Chemoradiotherapy Associated with Rapid Decline in Circulating Tumor DNA (ctDNA/cfDNA)
Rhea-AI Summary
PDS Biotech announces data demonstrating rapid decline in HPV circulating cell-free DNA (cfHPV-DNA) with lead candidate PDS0101 in combination with standard-of-care chemoradiotherapy (CRT) in cervical cancer patients
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.93%
Tags
none
-
News
PDS Biotech to Present at the LD Micro Main Event XVI
Rhea-AI Summary
PDS Biotech CEO to present at LD Micro Main Event XVI on October 4, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.15%
Tags
conferences
-
News
PDS Biotech Reschedules Key Opinion Leader Roundtable Addressing Current and Future Treatments for Recurrent/Metastatic HPV-Positive HNSCC and the Potential Application of PDS0101
Rhea-AI Summary
PDS Biotech reschedules Key Opinion Leader Roundtable on addressing treatments for HPV-positive head and neck cancer
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.92%
Tags
none
News
PDS Biotech to Participate in the 2023 Cantor Fitzgerald Global Healthcare Conference
Rhea-AI Summary
PDS Biotech CEO to participate in panel presentation at Cantor Fitzgerald Global Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.38%
Tags
conferences
-
News
PDS Biotech Announces PDS0202 Elicits Active Neutralization of Multiple Influenza Strains in Preclinical Studies
Rhea-AI Summary
PDS Biotech announces positive results for its investigational universal influenza vaccine PDS0202
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.12%
Tags
clinical trial
-
News
PDS Biotech to Host Key Opinion Leader Roundtable Addressing Current and Future Treatments for Recurrent/Metastatic HPV-Positive HNSCC and the Potential Application of PDS0101 on September 27, 2023
Rhea-AI Summary
PDS Biotech to provide updated VERSATILE-002 data on combination of PDS0101 and KEYTRUDA® in a KOL Roundtable event on September 27, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.79%
Tags
conferences
News
PDS Biotech to Participate at the H.C. Wainwright 25th Annual Global Investment Conference
Rhea-AI Summary
PDS Biotech to present at H.C. Wainwright conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.54%
Tags
conferences
-
News
PDS0202 Universal Influenza Preclinical Ferret Data to be Presented in Oral Lecture at 9th ESWI Conference
Rhea-AI Summary
PDS Biotech to present data on PDS0202 universal influenza vaccine at ESWI Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.17%
Tags
none
-
News
PDS Biotech Announces Data from IMMUNOCERV Phase 2 Trial Investigating PDS0101 and Chemoradiotherapy in Cervical Cancer to be Featured in Oral Presentation at the ASTRO 2023 Annual Meeting
Rhea-AI Summary
PDS Biotech announced that data from the IMMUNOCERV Phase 2 clinical trial investigating PDS0101 in combination with standard-of-care chemoradiotherapy for the treatment of cervical cancer will be presented at the ASTRO 2023 Annual Meeting.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.95%
Tags
clinical trial
News
PDS Biotech Reports Second Quarter 2023 Financial Results and Provides Business Update
Rhea-AI Summary
PDS Biotech submits final clinical protocol for Phase 3 trial, presents biomarker data at ESMO 2023, and discusses financial results. Lead drug candidate shows promising results in Phase 2 trial. Antibody-conjugated IL-12 to be presented at Cytokines 2023. Net loss for Q2 2023 increased due to R&D expenses.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.9%
Tags
earnings
Stock PDSB logo
PDS Biotechnology Corporation

Nasdaq:PDSB

PDSB Rankings

#4207 Ranked by Market Cap
#3526 Ranked by Stock Gains
N/A Ranked by Dividends

PDSB Stock Data

112.97M
35.41M
3.67%
22.93%
16.77%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
PRINCETON

About PDSB

pds biotechnology is a clinical stage biopharmaceutical company developing the next-generation of simpler, safer and more effective immunotherapies for cancer and infectious diseases. pds biotechnology’s proprietary versamune® platform vector is based on synthetic and biodegradable lipids which possess a very specific structure and positive charge. the lipids form nanoparticles which activate and are taken up very efficiently by the immune system. the therapeutic product consists of versamune® formulated with a harmless form of the protein or disease-causing agent associated with the particular disease (the antigen) which our immune systems can recognize and respond to. this antigen could be a unique protein expressed only in the cancer cells and not in healthy cells, or it could be a specific viral protein(s) from an infectious virus for example. pds is in the process of completing its first phase 1 human clinical trial in 2015 for pds0101, and has initiated design and preparati